Facible BioDiagnostics on Rialto Markets 2022

0
46

[ad_1]

Analytics

Security Type

Equity – Common

Reporting Date

07/29/2022

Likelihood of Max

Momentum

cold.svg

Create a free account today to gain access to KingsCrowd analytics.

Industry

Healthcare & Pharmaceuticals

Facible BioDiagnostics is raising funds on Rialto Markets through Reg A+ crowdfunding. The company has developed a new technology for diagnostic testing to deliver fast and accurate results in the detection of viruses, bacteria, and other contaminants. The technology is called Quantum-Logic Anazyme Analyte Detection (Q-LAAD) and is specifically used for COVID testing. Facible BioDiagnostics has signed an LOI with a distributor for 18 million units and estimates its gross profit margin to be 93.57%. Steven Burden, Clementine Gibard Bohachek, and Hunter Covert founded Facible BioDiagnostics in 2022. The current crowdfunding campaign has a maximum target of $40,000,000. The campaign proceeds will be used for research and development, clinical testing, and working capital.

Balance Sheet

Cash and Cash Equivalents

$449,114

Property, Plant and Equipment (PP&E)

$697,197

Total Assets

$1,432,437

Accounts Payable & Accrued Liabilities

$246,663

Long Term Debt

$8,805,465

Total Liabilities

$9,070,128

Total Stockholders’ Equity

$-7,637,691

Total Liabilities and Equity

$1,432,437

Statement of Comprehensive Income Information

Costs & Expenses Applicable to Rev

$2,205,884

Depreciation and Amortization

$135,815

Net Income

$-6,377,124

Earnings Per Share – Basic

$-0.29

Earnings Per Share – Diluted

$-0.09

Auditor: Assurance Dimensions

Financials as of: 07/28/2022

Create a free account today to gain access to KingsCrowd analytics.

Pay Monthly


Annually (Save 17%)

Edge

$12.42 /month
billed annually
Free portfolio tracking and KingsCrowd’s quantitative ratings on all raises.
Plan Includes:

Everything in Free, plus
Company specific “>
KingsCrowd ratings (excluding risk)
Advanced company search (
with ratings)
“>
Markets page filters and historical industry data

Get Edge Annual

Edge Pro

$41.58 /month
billed annually
Full site access including KingsCrowd’s qualitative analyst reports.
Plan Includes:
Everything in Edge, plus
Full access to detailed “>
Analyst Reports (e.g. Top Deal, Deal to Watch, Neutral, and Underweight)

Search and filter based on Analyst Reports
In-depth risk ratings for every raise

Get Edge Pro Annual

Thank you for your vote on Facible BioDiagnostics on Rialto Markets 2022

Thank you for your vote on Facible BioDiagnostics on Rialto Markets 2022



[ad_2]